Clinical trial · Observational
Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
Study on the Clinical Value of Circulating Immune Markers in Prognostic Evaluation of Postoperative Lung Cancer Patients
NCT07242482CI-TRIAL-00097668not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biomarkers / Blood | — | UNRESOLVED | — |
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Preoperative Peripheral Blood Immune Marker Analysis. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Recurrence-Free Survival
- timeFrame
- 3 years postoperatively
- description
- The time from the date of surgery to the first occurrence of disease recurrence, metastasis, or death from any cause.
Secondary outcomes (3)
- measure
- Overall Survival
- timeFrame
- 3 years postoperatively
- description
- The time from the date of surgery to death from any cause.
- measure
- Correlation between immune markers and clinicopathological features
- timeFrame
- Baseline (preoperative)
- description
- To analyze the associations between preoperative levels of ETASTs, Teff/Treg ratio, and clinicopathological characteristics such as TNM stage, pathological type, and driver gene mutation status.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 to 80 years. * Diagnosed with primary non-small cell lung cancer (NSCLC) and scheduled to undergo curative lung resection at the Department of Thoracic Surgery of our institution. * Postoperative pathological stage is IB (with tumor size \>4cm or high-risk factors: poor differentiation, vascular invasion, visceral pleural invasion, sub-lobar resection, etc.), IIA, IIB, or IIIB (according to the AJCC 8th edition). * ECOG performance status of 0 or 1. * Voluntarily signs the informed consent form. Exclusion Criteria: * Received any neoadjuvant therapy prior to surgery. * History of other active malignancies. * Diagnosed with severe autoimmune diseases, active infections, or immunodeficiency disorders. * Presence of severe cardiac, hepatic, or renal dysfunction. * Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.